Kineta (KA) Stock Price, News & Analysis

Company Overview

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.57 to $0.86
• 52-Week Range: N/A
• Volume: 530,700 shs
• Average Volume: 409,478 shs
• Market Capitalization: $7.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

KA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Kineta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kineta investors own include Intel (INTC), Motley Fool 100 Index ETF (TMFC), Argan (AGX), AST SpaceMobile (ASTS), AutoZone (AZO), Cadence Design Systems (CDNS) and Walt Disney (DIS).

Company Calendar

• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KA
• CUSIP: N/A
• CIK: 1445283
• Web: www.kinetabio.com
• Phone: (206) 378-0400
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,100,000.00
• Net Margins: N/A
• Pretax Margin: -345.77%
• Return on Equity: -1,044.95%
• Return on Assets: -336.46%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $5.44 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,254,000
• Free Float: 9,350,000
• Market Cap: $7.04 million
• Optionable: Not Optionable
• Beta: 0.46